Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Medical Genetics

Understanding Your PALB2 Result

At a Glance

A pathogenic PALB2 variant raises the risk of certain cancers by weakening DNA repair, but it does not mean you currently have cancer. Genetic counseling can clarify your personal risk, screening plan, family testing, and options for prevention or treatment.

Finding out you have a pathogenic variant (a disease-causing mutation) in your PALB2 gene can feel overwhelming. It is normal to experience a wide range of emotions, from anxiety and fear about the future to relief at having an explanation for a family history of cancer [1][2]. Some people feel a sense of “genetic guilt” regarding their children, while others feel empowered by the ability to take proactive steps for their health [3][2]. Whatever you are feeling is a valid response to significant medical news.

It is important to remember that having a pathogenic variant in PALB2 means you have an increased risk of developing cancer; it does not mean you currently have cancer.

The Biological “Bridge”

To understand what PALB2 does, it helps to think of your DNA as a set of instructions that constantly needs maintenance. Every day, your cells face “breaks” in their DNA. Your body has a specialized repair crew to fix these breaks. The most famous members of this crew are the BRCA1 and BRCA2 proteins.

PALB2 gets its name because it is the Partner And Localizer of BRCA2 [4]. It acts as a critical biological bridge:

  1. The Scout: When a DNA break occurs, BRCA1 acts as a scout that finds the damage [5].
  2. The Bridge: BRCA1 then recruits PALB2 to the site. PALB2 physically connects to BRCA1 at one end and BRCA2 at the other [6].
  3. The Repair: This connection allows BRCA2 to move into place and lead the actual repair of the DNA strand [4].

Without enough functional PALB2 protein, this bridge is broken. The repair crew cannot coordinate properly, and DNA damage may go unrepaired, which can eventually lead to the development of cancer cells [7].

Understanding Your Result: Zygosity and VUS

Pathogenic vs. VUS: Your lab report may indicate a “pathogenic” or “likely pathogenic” variant, which means the genetic change is known to disrupt the gene’s function and increase cancer risk. If your report instead notes a Variant of Uncertain Significance (VUS), this means there is not enough evidence to know if the change affects your health [8][9]. A VUS should not drive high-risk surgery or intensive screening changes outside of your standard family history recommendations. A tumor-only PALB2 finding also does not automatically establish inherited risk or imply that relatives need cascade testing.

Monoallelic vs. Biallelic: Every person has two copies of the PALB2 gene—one inherited from each parent. Most adult hereditary PALB2 results are heterozygous, but you must review the report with genetics to confirm your status.

  • Monoallelic (Heterozygous): This means you have one working copy of the gene and one copy with a pathogenic variant [7]. Having one mutation does not mean you have cancer; it means you have a higher risk of developing certain cancers [10].
  • Biallelic (Two Copies): In very rare cases, a person inherits a mutation from both parents, meaning they have no working PALB2 gene. This causes a serious pediatric condition called Fanconi Anemia Subtype N (FA-N) [11]. Children with FA-N often face physical growth challenges, bone marrow failure, and a very high risk of childhood cancers like leukemia or brain tumors [12][13].

The Role of Genetic Counseling

A genetic counselor is a specialist who helps you navigate the scientific, practical, and emotional aspects of this diagnosis. They are an essential part of your care team for several reasons:

  • Personalized Risk Assessment: They look beyond the “positive” result to analyze your specific mutation and your family’s unique history to give you a more accurate picture of your personal risk [14][15].
  • Cascade Testing: This is the process of testing your relatives (parents, siblings, and adult children) for the same mutation [16]. A counselor can help you decide how and when to share this news with your family [17].
  • Management Planning: They work with your doctors to ensure your screening schedule—such as mammograms and MRIs—aligns with the most current national guidelines [18][19].
  • Emotional Support: Counselors are trained to help you manage the “cancer worry” and distress that often peak shortly after receiving genetic results [1][20].

Moving Forward

Receiving this result marks the beginning of a new phase of proactive health management. While the news is heavy, it provides you and your medical team with a roadmap. By identifying the “broken bridge” in your DNA repair system, you can now use specialized tools—frequent screening, preventative options, and targeted therapies—to manage your health more effectively than was possible before you had this information [15][21].

Common questions in this guide

What does a positive PALB2 genetic test mean?
A pathogenic or likely pathogenic PALB2 result means the gene change is known or strongly suspected to disrupt DNA repair and increase the risk of certain cancers. It does not mean you currently have cancer. Your personal risk depends on the specific variant and your family history.
What does a PALB2 variant of uncertain significance mean?
A variant of uncertain significance, or VUS, means there is not enough evidence to know whether the genetic change affects health. A VUS should not by itself lead to high-risk surgery or major screening changes beyond recommendations based on your family history. Your genetics team can help explain what the result means while its significance remains uncertain.
What is the difference between monoallelic and biallelic PALB2 variants?
Monoallelic means one of your two PALB2 copies has a pathogenic variant; this raises cancer risk but does not mean you have cancer. Biallelic means variants affect both copies and can cause rare Fanconi anemia subtype N, a serious childhood condition involving growth challenges, bone marrow failure, and high childhood cancer risk. A genetics professional can confirm what your report shows.
Should my family members have PALB2 testing?
A genetic counselor can help determine whether parents, siblings, and adult children should be offered testing for the family variant. This process, called cascade testing, can clarify who may share the increased cancer risk and who may not. A PALB2 finding from a tumor-only test does not automatically prove an inherited variant or mean relatives need testing.
What screening is recommended after a PALB2 result?
Screening should be based on your specific variant, family history, and current national guidelines. Your genetic counselor and doctors may coordinate high-risk surveillance such as mammograms and breast MRI. Ask whether your hospital has a high-risk program to help organize care.
Can a PALB2 result affect cancer treatment?
If cancer develops, the specific PALB2 change may have implications for treatment choices, including whether targeted therapies are considered. Discuss this with an oncology team that can interpret the result in the context of your cancer and other test findings. A PALB2 result alone does not determine one treatment for every person.
What should I do after learning I have a PALB2 pathogenic variant?
Arrange genetic counseling to review the exact result, your family history, your screening plan, and options for sharing the information with relatives. Ask your care team about coordinated mammograms, breast MRI, and other risk-management choices. Emotional support is also appropriate because worry and distress are common after genetic results.

Get notified when new evidence is published on PALB2-related cancer predisposition.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Assessing Psychological Morbidity in Cancer-Unaffected BRCA1/2 Pathogenic Variant Carriers: A Systematic Review.

    Isselhard A, Lautz Z, Rhiem K, Stock S

    Current oncology (Toronto, Ont.) 2023; (30(4)):3590-3608 doi:10.3390/curroncol30040274.

    PMID: 37185387
  2. 2

    The psychological impact of genetic testing in childhood cancer: A systematic review.

    Van Hoyweghen S, Bm Claes K, de Putter R, et al.

    Psycho-oncology 2024; (33(1)):e6279 doi:10.1002/pon.6279.

    PMID: 38282231
  3. 3

    Psychological Impact of BRCA Genetic Testing: Analysis of Positive and Negative Affect Changes according to Test Results.

    Jung G, Hur SY, Wang SM, Choi YJ

    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2026; (24(3)):589-596 doi:10.9758/cpn.25.1383.

    PMID: 42528352
  4. 4

    Antiparallel Coiled-Coil Interactions Mediate the Homodimerization of the DNA Damage-Repair Protein PALB2.

    Song F, Li M, Liu G, et al.

    Biochemistry 2018; (57(47)):6581-6591 doi:10.1021/acs.biochem.8b00789.

    PMID: 30289697
  5. 5

    BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.

    Foo TK, Xia B

    Cancer research 2022; (82(18)):3191-3197 doi:10.1158/0008-5472.CAN-22-1535.

    PMID: 35819255
  6. 6

    Mutagenesis of the PALB2 WD40 domain identifies variants defective in interaction with BRCA2 and DNA repair.

    Gomes TT, Elias ABR, Huang H, et al.

    The Journal of biological chemistry 2025; (301(12)):110835 doi:10.1016/j.jbc.2025.110835.

    PMID: 41109346
  7. 7

    A germline PALB2 pathogenic variant identified in a pediatric high-grade glioma.

    Zhong Y, Schubert J, Wu J, et al.

    Cold Spring Harbor molecular case studies 2020; (6(4)) doi:10.1101/mcs.a005397.

    PMID: 32554798
  8. 8

    A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation.

    Brnich SE, Arteaga EC, Wang Y, et al.

    The Journal of molecular diagnostics : JMD 2021; (23(7)):847-864 doi:10.1016/j.jmoldx.2021.04.010.

    PMID: 33964450
  9. 9

    Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variants.

    Richardson ME, Bishop MFH, Holdren MA, et al.

    American journal of human genetics 2025; (112(10)):2266-2280 doi:10.1016/j.ajhg.2025.08.020.

    PMID: 40967221
  10. 10

    Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

    Yang X, Leslie G, Doroszuk A, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(7)):674-685 doi:10.1200/JCO.19.01907.

    PMID: 31841383
  11. 11

    Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2).

    McReynolds LJ, Biswas K, Giri N, et al.

    Cancer genetics 2021; (258-259()):101-109 doi:10.1016/j.cancergen.2021.10.001.

    PMID: 34687993
  12. 12

    A Hypomorphic PALB2 Allele Gives Rise to an Unusual Form of FA-N Associated with Lymphoid Tumour Development.

    Byrd PJ, Stewart GS, Smith A, et al.

    PLoS genetics 2016; (12(3)):e1005945 doi:10.1371/journal.pgen.1005945.

    PMID: 26990772
  13. 13

    Genotype-phenotype associations in Fanconi anemia: A literature review.

    Fiesco-Roa MO, Giri N, McReynolds LJ, et al.

    Blood reviews 2019; (37()):100589 doi:10.1016/j.blre.2019.100589.

    PMID: 31351673
  14. 14

    Genomic ascertainment of PALB2-related cancer predisposition: PALB2-related cancer predisposition.

    Stewart DR, Kim J, Haley JS, et al.

    medRxiv : the preprint server for health sciences 2026; doi:10.64898/2026.04.03.26349984.

    PMID: 41959818
  15. 15

    Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

    Tischkowitz M, Balmaña J, Foulkes WD, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(8)):1416-1423 doi:10.1038/s41436-021-01151-8.

    PMID: 33976419
  16. 16

    Cascade Genetic Testing for Hereditary Cancer Predisposition: Characterization of Patients in a Catchment Area of Southern Italy.

    Bilotta A, Lo Feudo E, Rocca V, et al.

    Genes 2025; (16(7)) doi:10.3390/genes16070795.

    PMID: 40725451
  17. 17

    Family Adjustment to Hereditary Cancer Syndromes: A Systematic Review.

    Gomes P, Pietrabissa G, Silva ER, et al.

    International journal of environmental research and public health 2022; (19(3)) doi:10.3390/ijerph19031603.

    PMID: 35162625
  18. 18

    NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.

    Daly MB, Pal T, Maxwell KN, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(10)):1000-1010 doi:10.6004/jnccn.2023.0051.

    PMID: 37856201
  19. 19

    Factors that differentiate cancer risk management decisions among females with pathogenic/likely pathogenic variants in PALB2, CHEK2, and ATM.

    Dean M, Tezak AL, Johnson S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2023; (25(11)):100945 doi:10.1016/j.gim.2023.100945.

    PMID: 37515473
  20. 20

    Quality of life, anxiety and cancer worry following hereditary cancer testing: a 6-month Swedish follow-up study.

    Heyman Y, Röjlar H, Hawranek C, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2026; (35(3)):70.

    PMID: 41677932
  21. 21

    Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.

    Lowry KP, Geuzinge HA, Stout NK, et al.

    JAMA oncology 2022; (8(4)):587-596 doi:10.1001/jamaoncol.2021.6204.

    PMID: 35175286

This page explains what a PALB2 result may mean for cancer risk, screening, and family testing for informational purposes only and does not replace professional medical advice. A genetic counselor and healthcare team should interpret your specific result.

Guide contents PALB2-related cancer predisposition
Research & Literature
02 Calculating Your Cancer Risk Factors